Evidence map›Paper›PMID 36117998›Full record

ArticleChinese herbal medicines2022

Zhi-E Fang, Yuming Guo, Zhilei Wang, Tingting He, Jiabo Wang, Zhaofang Bai, Xiaohe Xiao

Open access · goldAbstract read
In one paragraph

Article in Chinese herbal medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. TCMToxDB: a comprehensive database for the toxicological analysis of traditional Chinese medicines.Database : the journal of biological databases and curation · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhi-E FangDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Yuming GuoDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Zhilei WangDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Tingting HeDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Jiabo WangDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Zhaofang BaiDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Xiaohe XiaoDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Although some studies have linked Methods: A retrospective cohort study among hepatitis B virus (HBV)-monoinfected patients and non-HBV-monoinfected patients were performed. Patients over 18 years of age were eligible for inclusion. Prescription records of inpatients and outpatients were inquired to distinguish Results: There were 49 500 HBV and 133 148 non-HBV patients involved in the two cohorts. Among HBV patients (2 901 users; 46 599 nonusers), the prevalence of HCC in Conclusion: An obvious irrelevancy was found between the consumption of

Indexed as

aristolochic acidAsari Radix et Rhizomahepatitis B virus (HBV)hepatocellular carcinomasafety awareness

Identifiers

PMID36117998
PMCPMC9476760
OpenAlexW4220976171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.